Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncology. However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing. The agents, their properties, and their molecular targets are discussed in this review. [Mol Cancer Ther 2009;8(1):1–9]

[1]  A. Laird.  XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR , 2007 .

[2]  L. Cantley,et al.  Phosphoinositide kinases. , 1998, Annual review of biochemistry.

[3]  C. Billottet,et al.  A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.

[4]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[5]  Kristiina Vuori,et al.  The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures , 2007, Molecular Cancer Therapeutics.

[6]  J. Dodge,et al.  Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. , 1996, Journal of medicinal chemistry.

[7]  J. Baselga,et al.  Determinants of RASistance to anti-epidermal growth factor receptor agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Mario Amzel,et al.  Structural comparisons of class I phosphoinositide 3-kinases , 2008, Nature Reviews Cancer.

[9]  F. Liu,et al.  PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. , 2005, American journal of physiology. Endocrinology and metabolism.

[10]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[11]  C. Lindsley,et al.  The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2008, Current cancer drug targets.

[12]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[13]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[14]  R. Abraham,et al.  Mammalian target of rapamycin as a therapeutic target in oncology. , 2008, Expert opinion on therapeutic targets.

[15]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[17]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[18]  P. Vogt,et al.  Kinase inhibitors: vice becomes virtue. , 2006, Cancer cell.

[19]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[20]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Cotter,et al.  BCR-ABL Regulates Phosphatidylinositol 3-Kinase-p110γ Transcription and Activation and Is Required for Proliferation and Drug Resistance* , 2006, Journal of Biological Chemistry.

[22]  M. Waterfield,et al.  Using structure to define the function of phosphoinositide 3‐kinase family members , 1997, FEBS letters.

[23]  G. Mills,et al.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. , 2008, Cancer research.

[24]  Neal Rosen,et al.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. , 2005, Cancer cell.

[25]  J. Stock,et al.  Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.

[26]  S. Schreiber,et al.  The PIK-related kinases intercept conventional signaling pathways. , 1999, Chemistry & biology.

[27]  K. Shokat,et al.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. , 2008, The Biochemical journal.

[28]  J. Backer.  The regulation and function of Class III PI3Ks: novel roles for Vps34. , 2008, The Biochemical journal.

[29]  M. Waterfield,et al.  PI3-kinase inhibition: a target for drug development? , 2000, Molecular medicine today.

[30]  C. Vlahos,et al.  The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. , 1992, Biochemical and biophysical research communications.

[31]  Holger Gerhardt,et al.  Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration , 2008, Nature.

[32]  D. Hallahan,et al.  A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3′-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction , 2004, Cancer Research.

[33]  P. Wipf,et al.  Chemistry and biology of wortmannin. , 2005, Organic & biomolecular chemistry.

[34]  C. Benes,et al.  Class 1A PI3K regulates vessel integrity during development and tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[35]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[36]  R. Parsons.  Phosphatases and tumorigenesis , 1998, Current opinion in oncology.

[37]  L. Toral-Barza,et al.  Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy , 2008, Cancer biology & therapy.

[38]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[39]  M. Waterfield,et al.  Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.

[40]  P. Wipf,et al.  The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts , 2005, Molecular Cancer Therapeutics.

[41]  R. Phillips.  AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , 2000, Expert opinion on investigational drugs.

[42]  K. Shokat,et al.  A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.

[43]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[44]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[45]  Shaun P Jackson,et al.  Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. , 2007, The Biochemical journal.

[46]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[47]  J. Skotnicki,et al.  Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. , 2006, Journal of medicinal chemistry.

[48]  W L Stanford,et al.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. , 2000, Science.

[49]  Peter J. Alaimo,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. , 2004, Bioorganic & medicinal chemistry.

[50]  M. Zvelebil,et al.  Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. , 2008, Archives of biochemistry and biophysics.

[51]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[52]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[53]  R. Nussbaum,et al.  Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase , 2002, Mammalian Genome.

[54]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[55]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[56]  Roger L. Williams,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[57]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[58]  A. Toker.  Phosphoinositides and signal transduction , 2002, Cellular and Molecular Life Sciences CMLS.

[59]  J. Feliu,et al.  Cardiac toxicity: old and new issues in anti-cancer drugs , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[60]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[61]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[62]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[63]  G. Shapiro,et al.  Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor , 2007 .

[64]  P. Foster.  Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147 , 2007 .

[65]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[67]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[68]  D. Hallahan,et al.  Erratum: A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction (Cancer Research (July 2004) 64 (4893-4899) , 2004 .

[69]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[70]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[71]  P. Wipf,et al.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. , 2004, Molecular cancer therapeutics.

[72]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[73]  I. Takahashi,et al.  Wortmannin, a microbial product inhibitor of myosin light chain kinase. , 1992, The Journal of biological chemistry.